· AIM:Toinvestigatethepredictivefactorsforshorttermeffectsofintravitrealbevacizumabinjectionson centralsubfieldfovealthickness(CSFT)inpatientswith macularedema (ME)secondarytocentralretinalvein occlusion(CRVO).
INTRODUCTION
C entralretinalveinocclusion(CRVO)isacommon vasculardiseaseoftheretinathatoftenleadstosevere visionlossduetomacularedema(ME) [1] .Pathologically, CRVOoftenleadstoincreasedretinalthickness,cystoid macularedema(CME)andsubretinalfluid(SRF)becauseof thedisruptionoftheblood-retinalbarrier [2] .Theage-and gender-standardizedprevalenceofCRVOisestimatedtobe 0.80per1000 individuals [1] .Riskfactorsinclude hypertension,age,diabetes,glaucoma,highintraocular pressure,highbloodviscosity,cerebrovasculardiseasesand cardiovasculardiseases [3] .TherapeuticoptionsforME includefocallaserphotocoagulation [4] ,intravitrealsteroids [5] andsurgery [6] .However,someoftheseoptionsarestill controversial. Severalstudieshaveshowntheefficacyofintravitreal injectionsofanti-vascularendothelialgrowthfactor(VEGF) compoundssuchasbevacizumab,pegaptaniband ranibizumab [7] [8] [9] [10] [11] .VEGFlevelsareincreasedinthevitreous fluidofpatientswithCRVOandarepositivelycorrelated withretinalthickness,suggestingthatVEGFplaysan importantpartinthepathologicalprocessofCRVO [12] [13] . Therefore,anti-VEGFagentsweretriedandwereprovento beefficientinreducingMEandimprovingvisualacuity (VA) [7, 11, [14] [15] . However,notallpatientsbenefitfromanti-VEGFtherapy. Somestudieshaveindicatedthattheeliminationofthe thickeningresultingfromMEcanimprovetheVA [16] [17] ,but thattheresolutionoffovealthicknesswasincompleteorlate insomepatients.Severalstudiesobservedthatage,duration ofsymptoms,baselinecentralsubfieldfovealthickness 陨灶贼允韵责澡贼澡葬造皂燥造熏灾燥造援 9熏晕燥援 1熏 Jan.18, 圆园16 www.IJO.cn 栽藻造押8629原愿圆圆源缘员苑圆 8629-82210956 耘皂葬蚤造押ijopress岳员远猿援糟燥皂 (CSFT),andpresenceofCMEorSRFcouldbepotential predictorsforVA,buttheirconclusionsremainunclear [18] [19] [20] . Moreover,littleisknownaboutthepredictorsforthe outcomesofretinalthicknessafteranti-VEGFtreatments.A recentstudyhaveshownthatafter3moofranibizumab, opticalcoherencetomography(OCT)imagesprovided predictiveinformationforpatientswithCRVO [18] . Therefore,thepurposeofthepresentstudywastoinvestigate theefficacyandthepotentialpredictorsofshort-term (3-month)outcomesrelatedtoCSFTmeasuredbyOCTafter intravitrealinjectionofbevacizumabinpatientswithCRVO.
SUBJECTSANDMETHODS Subjects Thiswasaretrospectivestudyperformedin60
ChineseHanpatients(60eyes),whoreceivedatleastone injectionof1.25mgofbevacizumabintravitreallyforME duetoCRVOattheBeijingUniversityEyeCenter,Beijing UniversityThirdHospital,Beijing,China,betweenMay 2012andMay2014. Inclusioncriteriawere:1)MEduetoCRVOinvolvingthe fovea;2)minimalpretreatmentCSFTof 逸320 滋m;3) fluorescein angiography-confirmednon-ischemicCRVO (<10discdiameterofnon-perfusioninCRVO [21] );4) treatment-na觙ve;5)follow-upofatleast3mopost-treatment. [9] [10] [11] ,thecausesforthelackof responseinsomepatientswithMEduetoCRVOremain unknown [18] .Thepresentstudyshowedthatmost non-ischemicCRVOpatientshadanimmediateresponseto bevacizumabinjections.Moreover,theearlyresponders (CSFT<320 滋mat3mo)achievedbettervisualimprovements Baseline CME or CME+SRF 0.764 0.205-1.849 0.688 OR: Odds ratios; CI: Confidence interval; BCVA: Best-corrected visual acuity; logMAR: Logarithm of the minimum angle of resolution; CSFT: Central subfield foveal thickness; CME: Cystoid macular edema; SRF: Subretinal fluid. Final CSFT was used as the depdendent variable (<320 μm vs ≥320 μm). b Intragroup P-value; DM: Diabetes mellitus; HTN: hypertension; BCVA: Best-corrected visual acuity; logMAR: Logarithm of the minimum angle of resolution; CSFT: Central subfield foveal thickness; CME: Cystoid macular edema; SRF: Subretinal fluid.
thanthelateorincompleteresponders(CSFT 逸320 滋mat 3mo).Multivariateanalysisrevealedthatpatientswith favorableresponsetotreatmentwereolderandhadlower CSFTatbaseline.Thus,thefovealthicknessresponseto bevacizumabmaydependontheresolutionofCME,rather thanthepresenceofSRF.Patientswhowereolderthan60y achievedbetterresolutionofCMEandlowerCSFTat3mo. ThisissupportedbyBhisitkul [18] ,whoobservedthat earlyresponderstoranibizumabachievedbettervisual outcomesthanlateresponders,andthatearlyrespondershad aCSFTof250 滋morlessatbaseline;however,theydidnot observeanyeffectfromage. Inthepresentstudy,intravitrealbevacizumabtherapy resultedinasignificantshort-termimprovementofthemean VAandadecreaseinthemeanCSFTat3mo,whichis supportedbyrecentstudies [24] [25] .Thecorrelationbetweenthe improvementofVAandthedecreaseinCSFTwasalso observedbyBhisitkul [18] .Furthermore,CMEwas resolvedin53%ofpatientsafterthefirstinjectionwithout recurrenceat3mo,whichissupportedbystudiesby DeCroos [26] andHoeh [27] .Inthesetwoprevious studies,theresponsetothefirstinjectionwasthemost importantand seemedtobe predictiveofshort-term treatmentresults [26] [27] . Multivariateanalysisrevealedthatpatientswithfavorable retinalthicknessresponsetothetreatmentwereolderand hadlowerCSFTatbaseline,whereasbaselineVA,duration, andpresenceofCMEorSRFhadnopredictivevalue.Only afewstudieshaveexaminedbaselineCSFTasaprognostic factorforOCTtreatmentoutcomes [18] [19] ,butastudyreported nosignificantcorrelationbetweenbaselineCSFTandfoveal thicknessatthelastfollow-up [20] .Inthepresentstudy,lower baselineCSFTwasassociatedwithabetterresponseto bevacizumab. Thepresentstudysuggestedthattheearlyresponders(CSFT <320 滋mat3mo)hadatendencytoachievebettervisual improvementscomparedwithlateorincompleteresponders (CSFT 逸 320 滋mat3mo),withbetterresolutionofCME ( <0.001).Somestudieshavereportedthatthepresenceof SRFatbaselinedidnotinfluencetheresponseto bevacizumab [20, 28] .Inaddition,resultsofthepresentstudy showedthatSRFwaspresentatbaselinein40%ofpatients anddisappearedinmorethan90%ofpatientsat3moinboth groups.Noma [29] havesuggestedthatthevitreouslevels ofVEGFwerehigherinpatientswithCRVOandSRFthan inthosewithCMEalone,suggestingagreatereffectof bevacizumabinthesepatients.Comparedwiththenegative impactofSRF,theresolutionofCMEmightdeterminethe retinalthicknessandVAoutcomes.AsreportedbyBhisitkul [18] ,patientswhohadresidualCMEat3mohadaworse visualoutcomeat6mo.Thepresenceofcysticspacesmight bemoredisruptivetotheretinalarchitecture,predictingthat CMEwouldhaveanegativeimpactonvision. Interestingly,inthepresentstudy,olderpatientsachieved betterresolutionofCMEandlowerCSFTat3mo.Agehas beenproventobeariskfactorforretinalveinocclusion [21] , andyoungeragewasalwayspredictiveofbetterresponsefor VAoutcomes [19, 27, [30] [31] [32] .Inaddition,somestudieshavereported thatagehadnopredictivevalueforVAoutcomes [33] [34] .Few studiesreportedtheimpactofageonfovealthickness outcomes.Ach [19] suggestedthatthepatientswho showedbetterOCTresponseswereyounger,whichmaybe duetogenerallyhealthieroculartissuesinyoungerpatients. However,inthepresentstudy,youngeragemightbe predictiveoflateorincompleteresponseforfovealthickness outcomes.However,theseresultsshouldbeinterpretedwith cautionbecauseofthesmallsubgroupsize.Asweknow, youngerpatientswithCRVOmayhavegreaterassociation withinflammatoryconditionscomparedwitholderones [35] becauseinflammatorycytokinesmayplayanimportant role [33, 36] .Moreover,inflammatorycytokinesweremoreoften correlatedwithmorphologicchangesassessedbySD-OCT ratherthanVEGF-A [37] .AmoremarkeddecreaseinMEin youngerpatientsafterintravitrealanti-angiogenictherapy [21, 28, 38] .Therefore,VEGF inhibitionalonemaynotbesufficienttodecreasethe inflammatoryresponse,especiallyinyoungerpatientswith CRVO [37] .Accordingly,additionofananti-angiogenicagent maybemoreeffectiveinyoungerpatients. Thepresentstudyisnotwithoutlimitations.First,thesample sizewassmall.Althoughwecouldnotexcludetheeffectsof thesmallsamplesize,theimpactofageontheresponseto retinalthicknessoutcomesafterbevacizumabshouldbe underlined.Second,inspiteoftheabsenceofacontrol group,theretrospectivenatureofthestudywasalimitation initself.Inaddition,despitethefactthattheinterventionin ourcenterisbasedontheBranchRetinalVeinOcclusion: EvaluationofEfficacyandSafety(BRAVO)trial [39] ,the treatmentregimendonotfollowastricttreatmentalgorithm, butisbasedprimarilyonOCT-guidedtherapy,whichwas reportedbypreviousstudies [33, 40] .Finally,thefollow-up periodwasnotverylong(1and3mo)becausethesearethe standardpost-injectionfollow-upvisitsafterintravitreal injectionof bevacizumabin our center. Therefore, prospectivestudieswithlargersamplesizesarenecessaryto determine factors responsibleforthe responseto bevacizumabinthesepatients. Inconclusion,thepresentstudysuggeststhatintravitreal bevacizumabinjectionsgivenbyOCT-guideddosing regimenimprovedVAandCSFTinnon-ischemicCRVO patientsafter3mo.LowerbaselineCSFTandolderagewere goodpredictorsofshort-termCSFToutcomes.Further studieswithalargersamplesizearenecessarytovalidate theseconclusions.
